Interactions between Nef and AIP1 proliferate multivesicular bodies and facilitate egress of HIV-1 by Costa, Luciana J et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Retrovirology
Open Access Research
Interactions between Nef and AIP1 proliferate multivesicular 
bodies and facilitate egress of HIV-1
Luciana J Costa†1, Nan Chen†2, Adriana Lopes1, Renato S Aguiar1, 
Amilcar Tanuri1, Ana Plemenitas3 and B Matija Peterlin*2
Address: 1Molecular Virology Laboratory, Dep. of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, 2Departments of Medicine, 
Microbiology and Immunology, Rosalind Russell Medical Research Center, University of California at San Francisco, San Francisco, CA, USA and 
3Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Email: Luciana J Costa - ljcosta@biologia.ufrj.br; Nan Chen - nan.chen@ucsf.edu; Adriana Lopes - matija.peterlin@ucsf.edu; 
Renato S Aguiar - matija.peterlin@ucsf.edu; Amilcar Tanuri - matija.peterlin@ucsf.edu; Ana Plemenitas - ana.plemenitas@mf.uni-lj.si; B 
Matija Peterlin* - matija.peterlin@ucsf.edu
* Corresponding author    †Equal contributors
Abstract
Background: Nef is an accessory protein of primate lentiviruses, HIV-1, HIV-2 and SIV. Besides
removing CD4 and MHC class I from the surface and activating cellular signaling cascades, Nef also
binds GagPol during late stages of the viral replicative cycle. In this report, we investigated further
the ability of Nef to facilitate the replication of HIV-1.
Results: To this end, first the release of new viral particles was much lower in the absence of Nef
in a T cell line. Since the same results were obtained in the absence of the viral envelope using
pseudo-typed viruses, this phenomenon was independent of CD4 and enhanced infectivity. Next,
we found that Nef not only possesses a consensus motif for but also binds AIP1 in vitro and in vivo.
AIP1 is the critical intermediate in the formation of multivesicular bodies (MVBs), which play an
important role in the budding and release of viruses from infected cells. Indeed, Nef proliferated
MVBs in cells, but only when its AIP1-binding site was intact. Finally, these functions of Nef were
reproduced in primary macrophages, where the wild type but not mutant Nef proteins led to
increased release of new viral particles from infected cells.
Conclusion: We conclude that by binding GagPol and AIP1, Nef not only proliferates MVBs but
also contributes to the egress of viral particles from infected cells.
Background
Primate lentiviruses HIV-1, HIV-2 and SIV infect macro-
phages and T lymphocytes via CD4 and CCR5 or CXCR4
chemokine receptors, respectively. Infected individuals
eventually develop the acquired immunodeficiency syn-
drome (AIDS). The course of their disease varies greatly,
which depends on genetic factors and host immune
responses [1,2]. Another important determinant of dis-
ease progression is the viral accessory protein, the
misnamed negative factor or Nef. Indeed, adult rhesus
macaques and humans infected with lentiviruses lacking
Nef have very low levels of viral replication and little, if
any, evidence of disease [3-5]. Only with the reconstitu-
tion of their nef genes do these viruses start to replicate
robustly, which then leads to AIDS [6-8]. Thus, Nef has
been considered a critical factor for the production and
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infectivity of primate lentiviruses in the host, which is a
phenotype that is reproduced best in studies using pri-
mary cells in culture [9-12].
Nef is a small, myristylated protein that is expressed early
in the viral replicative cycle. It is found on cellular mem-
branes as a homodimer, where each subunit measures 27
to 32 kDa. Among all Nef proteins, the most conserved
region is the central core domain of 6 α helices and 5 β
sheets that binds many lipid, serine/threonine and tyro-
sine kinases as well as guanine nucleotide exchange fac-
tors and small GTPases [13]. The signalosome that is
assembled on Nef leads to downstream effector functions
and cytoskeletal rearrangements [14]. Near its N-terminus
is the binding site for CD4 and the C-terminal flexible
loop interacts with several subunits of adaptor protein
(AP) complexes as well as with other trafficking molecules
[15-20]. Thus, Nef also affects the movement of intracel-
lular organelles. Of interest, these functions can be linked,
as phosphoinositol 3-kinase (PI3K) also contributes to
the sequestration of major histocompatibility complex
(MHC) class I determinants [21].
In addition, Nef can accumulate in detergent resistant
microdomains (DRMs) or lipid rafts [22], and is incorpo-
rated into new viral particles [23,24]. It also augments the
infectivity of progeny virions, in part, by increasing the
incorporation of lipids into viral membranes [25]. To this
end, Nef not only induces the synthesis of cholesterol but
carries this lipid into viral particles [25]. These viral parti-
cles then fuse with DRMs on the recipient cell [26]. To
accomplish some of these chaperone functions, Nef binds
the transframe p6* protein from GagPol, which does not
exist in Gag [27]. Of interest, if Nef is retained near the
endoplasmic reticulum (ER) either as a naturally occur-
ring dominant negative Nef protein (NefF12) or by add-
ing the ER-retention signal (KKXX) to Nef (NefKKXX), no
viral particles are made and no Gag processing is observed
[27,28]. Thus, by biochemical and genetic criteria, Nef
binds GagPol and affects the replication of HIV-1 via its
association with viral assembly intermediates.
Recently, Nef has been demonstrated to proliferate multi-
vesicular bodies (MVBs) [29,30] and to facilitate the
egress of a variety of pseudotyped viruses from cells [31].
These studies suggest that Nef contributes directly to the
replication of HIV-1, possibly as a "modified" late (L)
domain. L domains of retroviruses and other RNA viruses
bind the tumor suppressor gene 101 (Tsg101) from the
Endosomal Sorting Complex Required for Transport I
(ESCRTI) [32-35] or the apoptosis linked gene 2 (ALG2)-
interacting protein 1 (AIP1) that bridges ESCRTI and
ESCRTIII [36-39]. With the help of PI3K, phosphoinositol
3 phosphate (PI3P), AAA ATPase Vps4, these E-Vps or
ESCRT proteins then create vacuoles into which vesicles
bud [40-42]. Indeed, these interactions are required for
the successful morphogenesis and release of viruses from
infected cells. In the case of HIV-1, whereas p6 from Gag
binds both Tsg101 and AIP1, p6* from GagPol contains a
completely different sequence and no such consensus
binding motif. However, we found that its binding part-
ner, Nef, not only contains such a site and binds AIP1 but
that it proliferates MVBs and leads to increased produc-
tion of viral particles from transformed cell lines and pri-
mary macrophages. Thus, Nef can contribute directly to
the egress of HIV-1 from infected cells.
Results
Nef increases levels of HIV-1 produced from SupT1 cells by 
a mechanism that is independent of CD4 and 
enhancement of viral infectivity
Previously, we demonstrated that Nef binds GagPol from
HIV-1 during late stages of the viral replicative cycle [27].
To determine what role this binding plays for the virus,
several CD4-positive cells were examined for the replica-
tion of HIV-1 in the presence and absence of Nef. Initially,
SupT1, Jurkat, CEM and MOLT4 cells were electroporated
with plasmids that directed the expression of HIV-1NL4-3
and mutant HIV-1NL4-3∆Nef proviruses and virus produc-
tion was measured 2 to 8 days later, both by levels of p24
capture ELISA and by western blotting of purified viruses
with α p24 antibodies. At day 2, we observed an 8-fold
decreased release of viral particles from SupT1 cells trans-
fected with the mutant
HIV-1NL4-3∆Nef provirus when compared to its wild type
HIV-1NL4-3 counterpart, whereas intracellular viral produc-
tion was at the same levels for both proviruses (Fig. 1A,
compare lanes 1 to 4). The earlier time point is presented
because at 2 days, we observed only a single round of viral
replication. Of interest, this decreased egress of mutant
HIV-1NL4-3∆Nef viral particles was not observed in Jurkat,
CEM and MOLT4 cells (data not presented). These find-
ings are in agreement with previous studies demonstrat-
ing the importance of Nef for the production of HIV-1
from SupT1 cells [43,44].
Since it was reported that Nef facilitates the release of HIV-
1 in T cells by decreasing the expression of CD4 on the cell
surface [45,46], a possible explanation for our finding
would be that SupT1 cells contain higher amounts of
CD4. In these studies, by binding HIV-1 Env, CD4
blocked the release of new viral particles and/or prevented
the infection of new cells via CD4 [45,46]. To exclude this
possibility, we pseudotyped mutant HIV-1NL4-3∆Env and
HIV-1NL4-3∆Env∆Nef proviruses that lack HIV-1 Env with
Env from the murine leukemia virus (MuLV Env) that
does not bind CD4, and obtained identical results (Fig.
1B). Again, at day 2 after the transfection, levels of p24 inRetrovirology 2006, 3:33 http://www.retrovirology.com/content/3/1/33
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the supernatant from these SupT1 cells were 8-fold higher
in the presence than in the absence of Nef (Fig. 1B, com-
pare lanes 1 and 2). Importantly, the MuLV Env does not
support a second round of viral replication in SupT1 cells.
Identical results were obtained when no Env was co-
expressed with HIV-1NL4-3∆Env and HIV-1NL4-3∆Env∆Nef
proviruses (data not provided). Thus, these assays do not
measure effects of Nef on the infectivity of HIV-1. This
result confirms that Nef is required for the egress of HIV-
1 by a mechanism other than the removal of CD4 from
HIV-1 Env and emphasizes the importance of Nef during
late stages of the viral replicative cycle in these cells.
Nef can substitute for the function of the L domain of Gag
The budding of HIV-1 is dependent on the consensus
Tsg101-binding motif (PTAP), which is located in p6 of
Gag [33]. To confirm that Nef could contribute to the
release of viral particles, we examined the ability of Nef to
rescue the production of VLPs from mutant Gag proteins
(Gag VLPs) with deletions (Gag∆ p6) or mutations
(GagLTAL) in the L domain. As presented in Fig. 2A, very
low levels of Gag VLPs were detected in supernatants from
cells, which expressed Gag∆ p6 alone (lane 2). However,
when Nef was linked to the C-terminus of the mutant
Gag∆ p6 polyprotein (Gag∆ p6.Nef), the production of
Gag VLPs was restored to wild type levels (Fig 2A, compare
lanes 1, 2 and 3). Intracellular levels of wild type Gag,
mutant Gag∆ p6 and mutant hybrid Gag∆ p6Nef proteins
are presented in the bottom panel of Fig. 2A. Thus, Nef
can substitute for the function of the L domain for the
production of Gag VLPs.
For the second strategy, Nef was expressed as a hybrid
Vpr.Nef protein, because the binding site for Vpr within
Gag is preserved in the mutant GagLTAL protein. Thus,
Vpr should bring Nef to Gag. When the mutant GagLTAL
protein was expressed with Vpr, a very inefficient produc-
tion of Gag VLPs was observed from 293T cells (Fig. 2B,
lane 1). However, the co-expression of the mutant
GagLTAL protein with increasing amounts of the Vpr.Nef
chimera augmented the release of these Gag VLPs (Fig 2B,
top panel, compare lanes 1, 2 and 3). We loaded equiva-
lent amounts of the mutant GagLTAL protein in the lysate
so that increased levels of Gag VLPs in the supernatant
could be compared directly (Fig. 2B, top and bottom pan-
els, compare lanes 1, 2 and 3). For the graph at the bottom
of Fig. 2B, which presents ratios between mutant GagLTAL
proteins in supernatants and lysates, amounts of mutant
GagLTAL proteins were measured by densitometry of dif-
ferent exposures of these western blots. From this graph
(Fig. 2B, bottom), we conclude that the Vpr.Nef chimera
can increase the release of these Gag VLPs up to 10-fold.
Thus, Nef can promote the egress of HIV-1 and Gag VLPs
from cells.
Nef contains a consensus-binding site for AIP1
From these results, we hypothesized that Nef could func-
tion as a "modified" L domain by helping to connect viral
assembly intermediates to the components of the ESCRT
machinery involved in HIV-1 budding. To confirm this
hypothesis we first generated multiple alignments of Nef
using the Clustal W algorithm [47,48] and inspected them
visually for the presence of sequences resembling the
already described L domain-binding motifs. We found the
YPLT sequence (residues from positions 135 to 138),
close to the C-terminal flexible-loop of Nef (Fig. 3). This
sequence resembles the YPLTS domain described as an
AIP1-binding site in p6 from HIV-1 and p9 from EIAV
[36]. It is important to note that this sequence has a high
degree of conservation among all isolates of HIV-1 but not
of HIV-2 and SIV (Fig. 3). Rather, Nef proteins from these
related lentiviruses contain another consensus AIP1-bind-
ing site at their N-termini (data not presented), which has
been implicated recently in high levels of SIV replication
in rhesus macaques [49].
Nef binds AIP1 in vitro and in vivo
Next, we investigated the ability of Nef to bind AIP1. To
detect this binding, plasmids directing the expression of
Nef increases levels of HIV-1 produced from SupT1 cells by a  CD4 independent mechanism Figure 1
Nef increases levels of HIV-1 produced from SupT1 
cells by a CD4 independent mechanism.A) SupT1 cells 
(1 × 107cells) were electroporated with 10 µg of plasmids 
directing the expression of wild type HIV-1NL4-3 and mutant 
HIV-1NL4-3∆Nef proviruses. 2 days later, supernatants and 
cells were collected and p24 levels were measured by p24 
capture ELISA (top panel). Viruses from cell supernatants 
were concentrated by ultracentrifugation. Viruses and cell 
lysates were processed for western blotting (WB) with α 
p24 antibodies (bottom panel). Bar graphs contain: Black 
bars, wild type HIV-1NL4-3 provirus; white bars, mutant HIV-
1NL4-3∆Nef provirus. Errors bars denote differences between 
three experiments performed in duplicate. (B) SupT1 cells (1 
× 107cells) were electroporated with 10 µg of plasmids 
directing the expression of mutant HIV-1NL4-3∆Env and HIV-
1NL4-3∆Env∆Nef proviruses together with 5 µg of an expres-
sion plasmid for the MuLV Env glycoprotein (MuLV Env). 2 
days later, supernatants and cells were collected and p24 lev-
els were measured as in (A). Error bars are as in (A).
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wild type and mutant Nef proteins at the putative consen-
sus AIP1-binding site were generated. Whereas the mutant
Nef∆ YPL protein contains a deletion of this motif, in the
mutant NefYPL protein, the YPL sequence has been
replaced by three alanines (Fig. 3, bottom). All Nef pro-
teins were expressed from the coupled transcription and
translation reactions with rabbit reticulocyte lysates in
vitro (IVT) (Fig. 4A, inputs). AIP1 was expressed and puri-
fied as the GST.AIP1 chimera from E. coli. GST alone was
expressed likewise and used as the negative control (Fig.
4A, inputs). Subsequent GST pulldowns revealed that Nef
binds AIP1 (Fig. 4A, lanes 1 and 2). Since the deletion of
the YPLTF sequence in the mutant Nef∆ YPL protein abol-
ished this binding, this interaction was also specific (Fig.
4A, lanes 3 and 4). Thus, Nef binds AIP1 and its consensus
AIP1-binding site is required for this interaction in vitro.
This binding was confirmed by co-immunoprecipitations
in cells. 293T cells co-expressed AIP1 and Nef proteins,
which were immunoprecipitated with α AIP1 antibodies.
After SDS-PAGE and transfer to membranes, western blot-
ting with α Nef antibodies revealed Nef-specific bands
(Fig. 4B). Again, AIP1 was only able to precipitate the wild
type but not mutant NefYPL proteins (Fig. 4B, compare
lanes 1, 2 and 3). Importantly, wild type and mutant Nef
proteins were expressed robustly in cells. Additionally,
since their migration patterns did not change, these muta-
tions most likely do not affect the structure of the protein.
Of note, similar confirmatory deletions and mutations
were used to map the AIP1-binding site in p6 [36]. Impor-
tantly, two independent approaches with two comple-
mentary mutant Nef proteins yielded identical results. We
conclude that Nef from HIV-1 binds AIP1 specifically in
vitro and in vivo.
Interactions between Nef and AIP1 are required for the 
proliferation of MVBs
It had been demonstrated that Nef increases the accumu-
lation of late endosomes in CEM and SupT1 cells [30].
More recently, Nef induced the proliferation of MVBs in
HeLa.CIITA cells [29]. Given that AIP1 plays an important
role in the formation of MVBs, we investigated if this find-
ing results from interactions between Nef and AIP1. Thus,
we expressed GFP, wild type Nef.GFP and mutant
NefYPL.GFP chimeras in HeLa.CIITA cells. Cell expressing
GFP were isolated by FACS, fixed and processed for elec-
tron microscopy. Under the electron microscope, MVBs
can be identified by their unique morphological appear-
ance, higher electron density and tightly packed internal
vesicles, which distinguishes them from other organelles
(Fig. 5A, bottom left panel) [29]. The number of MVBs in
each cell was counted directly under the electron micro-
scope from 30 images taken randomly from each sample.
Thus, at least 30 cells were examined and findings from
three independent experiments were averaged (Fig. 5A,
bottom right panel). In agreement with the previous pub-
lication [29], the expression of the wild type Nef protein
increased the accumulation of MVBs 3-fold in HeLa.CIITA
cells (Fig. 5, top and right bottom panels). Remarkably,
this effect was abolished with the mutant NefYPL protein,
which no longer binds AIP1. Indeed, in cells expressing
the mutant NefYPL.GFP chimera, the number of MVBs
was similar to that in control cells that expressed only
GFP. Thus, the proliferation of MVBs requires interactions
between Nef and AIP1.
Interactions between Nef and AIP1 are required for 
increased production of HIV-1 by Nef in primary 
macrophages
Mature viral particles accumulate inside late endosomes
in human mononuclear cells [50]. Later, the site of HIV-1
budding was proved to be in MVBs in macrophages
Nef rescues the release of Gag VLPs from the L domain- deleted and L domain-mutated Gag polyproteins Figure 2
Nef rescues the release of Gag VLPs from the L 
domain-deleted and L domain-mutated Gag polypro-
teins.A)Efficient production of Gag VLPs from a 
mutant hybrid Gag∆ p6.Nef chimera. Two days after 
the transfection, supernatants from 293T cells expressing 
wild-type Gag as well as mutant Gag∆ p6 proteins and the 
mutant hybrid Gag∆ p6.Nef chimera were collected and sub-
mitted to ultracentrifugation for the purification of Gag VLPs. 
Purified Gag VLPs and cell lysates were processed as in Fig. 1. 
Lane 1: Wild type Gag protein; Lane 2: Mutant Gag∆ p6 pro-
tein; Lane 3: Mutant hybrid Gag∆ p6.Nef chimera. 
(B)Hybrid Vpr.Nef protein increases the release of 
Gag VLPs from a mutated p6 and Pol-deleted virus. 
The mutant GagLTAL provirus was co-expressed with Vpr 
or with the Vpr.Nef chimera in 293T cells. Two days after 
the transfection, supernatants and cells were collected. Puri-
fied Gag VLPs and cell lysates were processed as in Fig. 1. 
Equivalent amounts of the mutant GagLTAL protein were 
loaded in the lysate to facilitate comparisons between GagV-
LPs in the supernatant. Gag VLPs were detected with α p24 
antibodies. Ratios between the mutant GagLTAL proteins in 
supernatants and lysates are presented in the bar graph 
below the western blots. Lane 1: Mutant GagLTAL protein 
with Vpr; Lanes 2 and 3; Mutant GagLTAL protein and 
increasing concentrations of the hybrid Vpr.Nef protein.
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[29,51]. Since by binding AIP1, Nef proliferates MVBs, we
investigated further viral replication in primary macro-
phages, which were derived from peripheral blood mono-
nuclear cells (PBMCs). Macrophages were allowed to
differentiate for 7 days. They were transfected and then
harvested 5 days later. Similar to data in Fig. 1, we
observed that in the absence of Nef, the production of the
mutant R5 virus, HIV-1ADA∆ Nef, was up to 6-fold lower
than of its wild type counterpart (HIV-1ADA) in primary
macrophages (Fig. 6A, compare bars 3, 4, 7 and 8). Fur-
thermore, the co-expression of the wild type but not
mutant Nef∆ YPL proteins with the mutant HIV-1ADA∆
Nef provirus rescued the production of progeny virions to
the same levels as were observed with the wild type HIV-
1ADA provirus (Fig. 6A, compare bars 1, 2, 5 and 6). These
experiments were repeated a total of 5 times with identical
results. Western blotting from cell lysates demonstrated
that levels of Gag and Nef were matched in cells express-
ing the wild type and mutant HIV-1ADA∆ Nef proviruses
(Fig. 6B, top and bottom panels), confirming that the
block in viral production was at a later step. Although ini-
tial experiments were performed using lipofectamine to
transfect primary macrophages, the resulting levels of p24
were low. Nevertheless, a total of 8 independent experi-
ments with lipofectamine also demonstrated the same
effects of Nef. Subsequently, these studies were repeated
using CaPO4, which led to 5-fold better tranfection effi-
ciencies (Fig. 6). Nevertheless, levels of expression
remained somewhat lower in our transfected than have
been observed in infected macrophages [51]. Identical
results were obtained when we used another R5 virus, the
wild type HIV-1ELI and mutant HIV-1ELI∆ Nef proviruses
(data not presented). Thus, Nef also increases the produc-
tion of HIV-1 from primary macrophages.
Discussion
In this report, we studied effects of Nef on the prolifera-
tion of MVBs and increased production of HIV-1 from
infected cells. Whereas in SupT1 cells and primary macro-
phages, Nef increased the extracellular accumulation of
Nef contains the consensus-binding site for AIP1 Figure 3
Nef contains the consensus-binding site for AIP1. Multiple alignments of sequences were generated by the Clustal W 
software and visually inspected for the presence of already described L domain motifs [47]. The AIP1-consensus binding site is 
highlighted. Consensus residues represent several subtypes of HIV-1. Below them are Nef sequences from HIV-2 and SIV that 
do not contain this consensus sequence. AIP1 binds elsewhere on these proteins. These sequences are from the Los Alamos 
database [48]. Below these sequences are diagrammed mutations that were introduced into Nef, one mutating the YPL 
sequence to three alanines (NefYPL), the other deleting the entire consensus motif (Nef∆ YPL).
CONSENSUS_B gyfpdwqnyt pgpgiryplt fgwcfklvpv epekveea-- negennsllh [200]
SF2 .......... .......... .......... ........-- .......... [200]
CONSENSUS_C .......... ....v..... .......... d.re....-- ......c... [200]
CONSENSUS_F1_4 .......... .......... .......... d..e..k.-- ......c... [200]
CONSENSUS_D_4 .-........ .......... .....e.... d.qe....-- t...d.c... [200]
CONSENSUS_CPZ .i........ ....v..... -........l t-.e..q.-- ...-d.i... [200]
HIV-2_2 ---------- ---------- ---------- ---------- ---------- [200]
HIV2_1 .iia...... s...v...mf ...lw..... dtsqeg.dte tdt.thc... [200]
HIV2UC2 .vi....... h...v...mc ...lw..... nmsqea.--- -dd.t.c.m. [200]
SIVmac .ii....d.. s.......k. ...lw..... nvsdeaq--- -.d.ehy.m. [200]
SIVmac239 .ii....d.. s.......k. ...lw..... nvsdeaq--- -.d.ehy.m. [200]
flexible loop
potential site for AIP1 interaction
NefYPL ………… pgpgiraaatfgwcfklvpv…………………………
Nef￿YPL ………… pgpgir gwcfklvpv…………………………Retrovirology 2006, 3:33 http://www.retrovirology.com/content/3/1/33
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new viral particles, in 293T cells, Nef rescued the produc-
tion of Gag VLPs from mutant Gag∆ p6 or Gagp6LTAL
proteins, which lacked the L domain. This phenotype was
correlated with interactions between Nef and AIP1, which
were documented by GST pulldowns and co-immunopre-
cipitations in cells. Importantly, this association was spe-
cific, as mutations in the conserved YPL motif in Nef
abolished this binding and eliminated effects of Nef on
the proliferation of MVBs and release of viral particles. We
conclude that by connecting GagPol and AIP1, Nef acts as
a chaperone the production and optimal egress of HIV-1
from infected cells.
Importantly, we used a transformed cell line as well as pri-
mary cells, especially since effects of Nef are most pro-
nounced in PBMCs and in the infected host [3-12]. Since
we did not observe the same phenotype in Jurkat, CEM
and Molt4 cells, the targeting of viral assembly intermedi-
ates to the cell surface rather than intracellular organelles
must also be more efficient in these cells. Indeed, in sharp
contrast to macrophages, no budding into MVBs had been
observed in these other T cell lines [50,51]. Importantly, a
role for CD4 could be excluded since the egress of pseudo-
typed viral particles, which contained the MuLV Env that
does not bind CD4 instead of HIV Env, from SupT1 cells
and that of wild type progeny virions from macrophages
that express low levels of CD4, were impacted identically
by Nef. In addition, it was important to confirm this effect
of Nef with mutant Gag proteins bearing deletions or
mutations in p6, as this assay represents an important
genetic proof for interactions between viral proteins and
the ESCRT machinery [27,33]. We also confirmed the spe-
cificity of binding for AIP1 by deletions and mutations of
the consensus YPL motif in Nef. For morphological stud-
ies, we used HeLa.CIITA cells, which express the class II
transactivator (CIITA) and hence MHC class II [52]. There
were several reasons for this choice. First, the effect of Nef
on the proliferation of MVBs had been documented in
these cells [29]. Second, they contain MHC class II com-
partments (MIICs), which are MVBs for antigen process-
ing and presentation by this pathway. Since their
composition had been examined extensively in these
cells, we could conclude that our dense vacuoles filled
with vesicles were MVBs by morphological criteria alone
[29,53]. In addition, increased levels of MVBs in our study
were identical to those already reported [29,30]. Impor-
tantly, the mutation of the AIP1- binding site in Nef abol-
ished this proliferation.
How do these findings fit into our view of Nef? Although
effects of Nef in infected cells are multifactorial, above all,
Nef is required for high levels of viral replication and the
progression to AIDS in the infected host [3-5]. In primary
cells, Nef also increases levels and infectivity of progeny
virions [12,54,55]. Cellular activation by Nef has been
implicated in low but detectable levels of viral replication
in unstimulated PBMCs [22,56]. However, even after the
stimulation with PHA, levels of progeny virions from
mutant HIV-1∆ Nef proviruses are still 5-fold lower when
compared to those with wild type proviruses in PBMCs
[57]. These findings suggested an additional role for Nef
in increasing viral production, possibly during the mor-
phogenesis and release of new virions. To this end, first,
Nef binds p6* in GagPol [27], which means that Nef trav-
els with viral assembly intermediates inside cells and is
incorporated into new viral particles. This association
found strong genetic support when two different Nef pro-
teins, one the naturally occurring allele of Nef (NefF12),
the other engineered artificially from NefNL4-3
(NefKKXX), could retain GagPol near the ER and block
subsequent processing and release of viral particles
[27,28]. Second, Nef stimulates transcription from the
viral LTR as well as of many cellular genes [58-60], which
include those involved in cholesterol biosynthesis [61].
Indeed, Nef also binds cholesterol and can be found in
DRMs [25], although one study disputes this localization
[62]. In addition, like DRMs, internal vesicles of MVBs are
enriched in cholesterol and harbor most of the cholesterol
from the endocytic pathway [63]. Third, Nef binds PI3K,
Nef binds AIP1 in vitro and invivo Figure 4
Nef binds AIP1 in vitro and invivo.(A)Nef binds AIP1 
in vitro. GST and GST.AIP1 fusion proteins were expressed 
in E. coli and purified by glutathione S-transferase beads. They 
were incubated with V5 epitope-tagged wild type Nef and 
mutant Nef∆ YPL proteins expressed in IVT. Bound proteins 
were resolved by 10% SDS-PAGE followed by western blot-
ting with α V5 antibodies. GST was used as the negative con-
trol (top right panel, lane 2). 10% of input proteins (inputs) is 
presented to the left of GST pulldowns. (B) Nef binds 
AIP1 in cells. HA epitope-tagged AIP1 protein was 
expressed alone or with the wild type and mutant NefYPL 
proteins in 293T cells. Cells were disrupted by dounce 
homogenization in hypotonic buffer containing protease 
inhibitor cocktails, followed by incubation with α HA poly-
clonal antibodies and protein-G beads. After the immunopre-
cipitation, western blotting was performed using α Nef 
antibodies (top left panel). A control western blot for 10% of 
input proteins was performed with α Nef and α AIP1 anti-
bodies (bottom left panels).
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whose kinase activity is required for the formation of
MVBs [42,64,65]. To this end, it is of interest that wort-
mannin, an inhibitor of PI3K, blocks the release of viral
particles from cells [66]. Finally, why would the virus
require a "modified" L domain, when ratios of Gag to
GagPol are 20:1 in viral particles? Possibly, because Gag-
Pol is bulkier and/or otherwise contains additional reten-
tion signals in Pol, which represents one half of the
polyprotein. Possibly, because Nef forms oligomers, it
could increase the size of viral assembly intermediates
that would be optimal for the targeting and egress of viral
particles from the infected cell. Otherwise, Nef contains
additional motifs that might be attractive to the virus at
this stage of its replicative cycle. PI3K and lipids have been
mentioned already, but Nef also associates with addi-
tional trafficking and signaling molecules. As both Nef
and gp41 interact with AP complexes, some of these
might facilitate the loading of Env onto viral particles
[67]. Others cause cytoskeletal rearrangements and
increase the local polymerization of actin, which is
required not only for the formation of pseudopodia, from
which virions bud, but also for the integrity of viral parti-
cles themselves [14,68]. In support of these findings, a
recent study found that SIV Nef not only augments the
incorporation of many retroviral glycoproteins onto Gag
of SIV by increasing their co-localization in late endo-
somes but leads to greater egress of these pseudotyped
viral particles from infected cells [31].
Conclusion
From these studies emerges an additional effect of Nef on
viral replication. During late stages of the viral replicative
cycle, Nef behaves like a chaperone for HIV-1. By interact-
ing with viral structural proteins and the ESCRT machin-
ery, it facilitates the egress of optimally infectious progeny
virions from infected mononuclear cells Future studies
will evaluate the role of PI3K in this process as well as con-
firm these findings in the primate model of AIDS, with
SIV in rhesus macaques.
Methods
Antibodies
Monoclonal α HA epitope (F7) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), monoclonal α V5 (Invitrogen,
Carlsbad, CA), monoclonal α FlagM2 (Sigma-Aldrich, St.
Louis, MO), monoclonal α Nef [25], and mouse α p24
(AG3.0) antibodies were used as first antibodies to detect
epitope-tagged proteins, Nef and Gag, respectively. Sec-
ondary HRP-conjugated anti-mouse antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA) were detected by
enhanced chemilumnescence (ECL, Amershan Bio-
sciences, Evanston, IL). α AIP1 antibodies were a kind gift
of Wesley Sundquist (U. of Utah, Salt Lake City, UT)
Plasmid constructions
Plasmid DNAs encoding replication-competent HIV-1
proviruses were from HIV-1NL4-3 [69]. The nef-deleted var-
iant NL4-3∆ Nef was generously provided by John Gua-
telli (U. of California, San Diego, CA). Proviral infectious
clones for the macrophage-tropic viruses ADA and ELI,
and the same clones disrupted for the Nef ORF (ADA∆
Nef, ELI∆ Nef) where provided by Marcelo Soares (Federal
University, Rio de Janeiro, Brazil), and are described else-
where [70,71]. Plasmid DNAs encoding env-deleted, env
plus  nef-deleted proviruses, and MLV-env, were kindly
provided by Hirofumi Akari (NIH, Bethesda, MD) and are
described elsewhere [72].
The Nef expression plasmid was generated by the amplifi-
cation of the nef  gene from the NL4-3 provirus and
inserted into pcDNA3.1D (Invitrogen) at the TOPO site.
This plasmid was used to derive the expression plasmids
for the mutant Nef∆ YPLF (Nef from NL4-3, residues
deleted from positions 135 to 138), and the mutant
NefYPL (Nef from NL4-3, mutated residues from posi-
tions 135 to 137 to alanines) proteins, by standard muta-
geneses. The human Aip1 cDNA was obtained from the
American Type Culture Collection and was amplified by
PCR with Bam HI (5') and EcoRI (3') restriction sites and
inserted into pEF-BOS-HA (to obtain the HA epitope-
Interactions between Nef and AIP1 are required for the pro- liferation of MVBs Figure 5
Interactions between Nef and AIP1 are required for 
the proliferation of MVBs. HeLa.CIITA cells were trans-
fected with plasmids, which directed the expression of GFP, 
Nef.GFP, or mutant NefYPL.GFP chimeras (top panels). GFP-
positive cells were isolated by FACS and fixed before ultra-
thin sectioning was performed. MVBs were identified by their 
unique morphology (bottom left panel) under the electron 
microscope (indicated by arrows). Numbers of MVBs of each 
cell type were counted directly under the electron micro-
scope from 30 profiles randomly taken from each sample. 
Bar graphs contain: White bars, GFP control; black bars, Nef; 
striped bars, mutant Nef.YPL protein.The black bar inside the 
EM panels measures 1 µm.
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tagged AIP1 protein) and into pGEX-4T1 (Pharmacia, Pis-
cataway, NJ)(to obtain the GST.AIP1 fusion protein).
pENX, which expresses Gag without p6, Env, Rev and Tat
[33], was used to create pENX.Flag.Nef, which has a Flag
eptiope-tagged Nef ORF at the C-terminus of the Gagp7
ORF. This plasmid expressed the mutant Gag∆ p6.Nef chi-
mera. pNL-∆ pol was derived from pNL-, which bears two
mutations in the Gagp6 L domain (PTAP to LTAL). To
generate the pNL-∆ pol plasmid, the entire pol  gene
together with the Vif and the Vpr ORFs were removed by
Bcl I-Sal I digestion, treated with Klenow enzyme and fur-
ther ligated with the T4 DNA ligase (both from Invitro-
gen). This plasmid expressed virus like particles (VLPs)
that did not bud from cells. To generate the expression
plasmid for the Myc.Vpr protein (pEF.Myc.Vpr), the vpr
gene from HIV-1NL4-3 was inserted into pEF.BOS.Myc. For
the expression of the hybrid Myc.Vpr.Nef protein, the nef
gene from HIV-1NL4-3  was inserted into pEF.Myc.Vpr
downstream from the vpr gene.
Cells and transfections
293T and HeLa.CIITA cells were grown in DMEM with
10% FCS and antibiotics. Transfections were performed
using Lipofectamine (Invitrogen). SupT1 cells were grown
in RPMI1640 medium with 10% FCS, antibiotics and L-
glutamine. Cells were electroporated using a BioRad elec-
troporator (BioRad USA Life Sciences, Hercules, CA) as
follows: 1 × 107 cells in the presence of 10 µg of DNA, elec-
troporated at 200 V and 995 µF. Primary macrophage cul-
tures were obtained from Peripheral Blood Mononuclear
Cells (PBMCs) by their adherence to plastic. Briefly,
PBMCs were obtained from buffy coats of anonymous,
healthy blood donors and separated by centrifugation
over Ficoll-Paque (Amershan Biosciences, Evanston, IL).
107 cells were incubated in DMEM with 5% human serum
type A and antibiotics. PBMCs were left to sit on TC25
plastic bottles for 7 days. Transfections were performed
using CaPO4 protocols (Stratagene, Carlsbad, CA). Trans-
fected cells were analyzed 5 days later for production of
viral partcles and intracellular levels of Nef.
Virus and Gag VLP production, virion and Gag VLP 
isolation and Gag expression
To assess effects of Nef during the production of new viral
particles, SupT1 cells were electroporated and macro-
phages were transfected with proviral DNAs and Nef
expression plasmids at 1:1 molar ratios. 4 to 8 days later,
cells and cell culture supernatants were harvested. The co-
expression of mutant HIV-1NL4-3∆ Env or HIV-1NL4-3∆
Env∆ Nef (which lacks the nef gene) plasmids with the
MuLV Env at equivalent amounts generated pseudotyped
viruses. For the evaluation of Gag VLPs, 293T cells were
transfected with the pENX and the pENX.Flag.Nef proviral
clones. 293T cells were also transfected with the pL- and
pNL-∆ pol proviral clones together with the Vpr or
Vpr.Nef fusion plasmids at different proportions of each
plasmid, ranging from 1:1 to 1:5 of the pL- or pNL-∆ pol
to the Vpr or hybrid Vpr.Nef plasmids. pENX and pL were
kind gift of Paul Bieniasz (ADARC, NYC, NY) [36]. Cul-
ture supernatants were clarified at low-speed centrifuga-
tion, cleared through a 0.45 µm-pore-size filter (Millipore,
Bedford, MA) and followed by ultracentrifugation
through a 20% sucrose cushion at 100,000 × g for 1.5 h.
Pellets were suspended in 1 × PBS overnight at 4°C.
Viruses were lysed in SDS-loading buffer and viral protein
contents were analyzed by western blotting. Quantifica-
tion of virion production was performed by p24 capture
ELISA (PerkinElmer/NEN Life Science Products, Boston,
MA). Cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer (150 mM NaCl, 50 mM Tris [pH 7.2], 1%
Triton X-100, 0.1% sodium dodecyl sulfate [SDS]), and
viral protein content analyzed by western blotting. Cell-
associated viral proteins were quantified as above.
Interactions between Nef and AIP1 increase the production  of HIV-1 from primary macrophages Figure 6
Interactions between Nef and AIP1 increase the pro-
duction of HIV-1 from primary macrophages. (A) 
Only the wild type Nef protein can rescue the pro-
duction of mutant viruses in macrophages. Macro-
phages were derived from PBMCs by adherence to plastic in 
the presence of 5% human serum. 7 days after differentiation, 
macrophages were transfected with wild type HIV-1ADA and 
mutant HIV-1ADA∆ Nef proviruses, or co-transfected with 
HIV-1ADA∆ Nef provirus with the wild type Nef or mutant 
Nef∆ YPL proteins. 5 days after the transfection, superna-
tants (S) and cell lysates (L) were examined for the presence 
of viral particles by the p24 capture ELISA. Bar graphs con-
tain: Black bars, HIV-1ADA alone or the mutant HIV-1ADA∆ 
Nef provirus with Nef; white bars, the mutant HIV-1ADA∆ 
Nef provirus; striped bars, the mutant HIV-1ADA∆ Nef provi-
rus with the mutant Nef∆ YPL protein. Errors bars denote 
differences between 5 independent experiments performed 
with the CaPO4 transfection protocol. (B)Expression of 
wild type and mutant viruses and wild type and 
mutant Nef proteins were equivalent in cells.Cell 
lysates from transfected macrophages were obtained concur-
rently and processed as in Figs. 1, 2, and 4.
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Protein purification, in vitro translation and GST 
pulldowns
The GST.AIP1 fusion protein was expressed in the
BL21(DE3)pLysS strain of E. coli (Novagen, Madison, WI)
and purified using Glutathione Sepharose beads (GE
Healthcare Bio-Sciences AB, Uppsale, Sweden) with a
modified lysis buffer (50 mM Hepes [pH 7.8], 100 mM
KCl, 1% Triton X-100, 2 mM EDTA, 0.1 mM PMSF, and 1
µg/ml lysozyme). Coomassie blue staining of SDS-PAGE
was used to check the purity of the GST.AIP1 chimera.
Amounts of protein were determined by a protein assay
kit (BioRad, Hercules, CA). Wild type and mutant Nef
proteins were transcribed and translated using the rabbit
reticulocyte in vitro (TNT, Promega, Madison, WI). SDS-
PAGE and western blotting using αV5 antibodies was
used to assess the quality of translated proteins. For in vitro
binding assays, 0.5 µg of immobilized GST or hybrid
GST.AIP1 proteins were incubated with 5 µl of V5
epitope-tagged proteins for 4 h at 4°C in 750 µl of CHAPS
buffer (50 mM Tris-HCl [pH 7.4], 0.05 mM EDTA, 10 mM
CHAPS and protease inhibitors). Beads were then washed
5 times in the same buffer and subjected to SDS-PAGE
and western blotting.
Co-Immunoprecipitation
293T cells were transfected with 0.5 µg of pCR.AIP1.HA
[40] alone or co-transfected with 0.5 µg of plasmids
expressing wild type or mutant NefYPL proteins. 36 h after
the transfection, cells were harvested, washed, and dis-
rupted by dounce homogenization in hypotonic buffer
containing protease inhibitor cocktails (Sigma-Aldridge,
Saint Louis, MI). After removing nuclei and unbroken
cells, 5 µg/ml of α HA antibodies (Santa Cruz Biotech,
Santa Cruz, CA) was added to the supernatant followed by
proteinG-beads (GE Healthcare Bio-Sciences AB, Uppsale,
Sweden). Immunoprecipitations were resolved by 12%
SDS-PAGE, and Nef proteins were detected by western
blotting using α Nef antibodies.
Electron microscopy
HeLa.CIITA cells were transfected with peGFPN1 (Clon-
tech Laboratories, Mountain View, CA) expressing GFP,
Nef.GFP, or mutant NefYPL.GFP fusion proteins by
Fugene6 (Roche Applied Science, Indianapolis, IN). 48
hours after the transfection, GFP-expressing cells were
sorted by FacsVantage and fixed in a mixture of 3% glutar-
aldehyde and 1% paraformaldehyde, 0.1M cacodylate
buffer, pH 7.4 prior to the process for ultra thin section-
ing. 30 images of each sample were taken randomly, and
the numbers of MVBs were quantified.
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